Head & neck · 2025
Surgical Versus Non-Surgical Treatment of Advanced Oropharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
СтатьяСистематический обзорМетаанализСравнительное исследованиеПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Scharner Megan K, Owen Johnny M, Nguyen Shaun A, Kejner Alexandra E, Newman Jason G, Brennan Emily, Albergotti W Greer
Аннотация
BACKGROUND: This review aims to compare survival outcomes of surgical versus non-surgical treatment of advanced-stage OPSCC.
METHODS: CINAHL, Cochrane Library, PubMed, and Scopus were searched. Studies comparing the survival of patients with advanced OPSCC treated surgically (±adjuvant therapy) or non-surgically were included. Meta-analyses hazard ratio (HR) and proportions (%) were performed for the outcomes of 2-, 3-, and 5-year overall (OS), disease-free (DFS), disease-specific (DSS), and relapse-free (RFS) survival.
RESULTS: Forty-four studies reporting on (N = 35 681) patients were included, with a mean age of 58.9. For advanced-stage disease, primary treatment with surgery and chemoradiotherapy (CRT) demonstrated the best 5-year OS, at 67.1% (95% CI 55.6-77.6). Survival outcomes favored Surgery + CRT over other primary treatment modalities.
CONCLUSIONS: Surgical treatment with adjuvant CRT may be associated with better OS outcomes compared with non-surgical treatment. Further research is needed to determine superior treatment modalities in OPSCC subgroups, such as HPV+ tumors.
METHODS: CINAHL, Cochrane Library, PubMed, and Scopus were searched. Studies comparing the survival of patients with advanced OPSCC treated surgically (±adjuvant therapy) or non-surgically were included. Meta-analyses hazard ratio (HR) and proportions (%) were performed for the outcomes of 2-, 3-, and 5-year overall (OS), disease-free (DFS), disease-specific (DSS), and relapse-free (RFS) survival.
RESULTS: Forty-four studies reporting on (N = 35 681) patients were included, with a mean age of 58.9. For advanced-stage disease, primary treatment with surgery and chemoradiotherapy (CRT) demonstrated the best 5-year OS, at 67.1% (95% CI 55.6-77.6). Survival outcomes favored Surgery + CRT over other primary treatment modalities.
CONCLUSIONS: Surgical treatment with adjuvant CRT may be associated with better OS outcomes compared with non-surgical treatment. Further research is needed to determine superior treatment modalities in OPSCC subgroups, such as HPV+ tumors.